CRIO Announces Partnership with Pluto Health
CRIO in partnership with Pluto Health has announced the development of an integration between clinical care and clinical research. CRIO's Medical Records API delivers electronic medical records and other health histories, alongside clinical care coordination. The Pluto Health team then provides ongoing health maintenance support for potential participants. All this information is shared with patients, and with patient consent, can be shared with their clinicians and directly to principal investigators (PIs) at clinical research sites.
CRIO's partnership with Pluto Health leverages the recent trends towards patient centricity within clinical trials, focusing on addressing the patient journey in its entirey. It delivers a method to support patients' care pathways through clinical coordination, while streamlining PI workflow, and enabling patient control over their health information.
This approach goes beyond PIs access to EMR data. The approach reviews and reconciles health status before entry into the EDC, and offers care coordination tools to advance patient care alongside clinical research operations. Once review and reconciliation are completed, the source records are populated in the EDC and remote monitors can view the underlying sanitized medical records with principal investigator annotations, along with the source records. This level of transparency enhances sponsor oversight of quality and patient safety.
Reference
CRIO Announces Partnership with Pluto Health to Expand and Accelerate Clinical Trial Access. (2023, July 19). Cision PR Newsire.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
